Inventor
WANG SHIMIAO
US31 patents
⚠️ This page may combine multiple inventors who share the name “WANG SHIMIAO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALLERGAN INC
15 patentsUS7060844B2Jun 13, 2006
(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
ALLERGAN INC29 citations92
US9371314B2Jun 21, 2016
Pyridyl benzothiophenes as kinase inhibitors
ALLERGAN INC3 citations73
US9233968B1Jan 12, 2016
Kinase inhibitors
ALLERGAN INC5 citations73
US7977351B2Jul 12, 2011
Heteroaryl dihydroindolones as kinase inhibitors
ALLERGAN INC3 citations62
US9359336B2Jun 7, 2016
Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
ALLERGAN INC1 citations61
US7915443B2Mar 29, 2011
Sulfoximines as kinase inhibitors
ALLERGAN INC5 citations60
US10669265B2Jun 2, 2020
Pyridyl benzothiophenes as kinase inhibitors
ALLERGAN INC0 citations52
US10633373B2Apr 28, 2020
Pyridyl benzothiophenes as kinase inhibitors
ALLERGAN INC0 citations52
US9868726B2Jan 16, 2018
Pyridyl benzothiophenes as kinase inhibitors
ALLERGAN INC0 citations52
US10011593B2Jul 3, 2018
Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
ALLERGAN INC0 citations51
US9650366B2May 16, 2017
Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
ALLERGAN INC0 citations51
US9266869B2Feb 23, 2016
Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors
ALLERGAN INC1 citations51
US9567324B2Feb 14, 2017
Substituted nicotinamide derivatives as kinase inhibitors
ALLERGAN INC0 citations41
US9403803B2Aug 2, 2016
Indole-3-carboxamides as kinase inhibitors
ALLERGAN INC0 citations41
US9353093B2May 31, 2016
Indole-1-carboxamides as kinase inhibitors
ALLERGAN INC0 citations41
CRINETICS PHARMACEUTICALS INC
14 patentsUS10981894B2Apr 20, 2021
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
CRINETICS PHARMACEUTICALS INC6 citations84
US10875839B2Dec 29, 2020
Somatostatin modulators and uses thereof
CRINETICS PHARMACEUTICALS INC5 citations84
US10604507B2Mar 31, 2020
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
CRINETICS PHARMACEUTICALS INC7 citations84
US10597377B2Mar 24, 2020
Somatostatin modulators and uses thereof
CRINETICS PHARMACEUTICALS INC8 citations84
US10562884B2Feb 18, 2020
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
CRINETICS PHARMACEUTICALS INC7 citations84
US10351547B2Jul 16, 2019
Somatostatin modulators and uses thereof
CRINETICS PHARMACEUTICALS INC9 citations84
US9902703B2Feb 27, 2018
Somatostatin modulators and uses thereof
CRINETICS PHARMACEUTICALS INC8 citations84
US9896432B2Feb 20, 2018
Somatostatin modulators and uses thereof
CRINETICS PHARMACEUTICALS INC11 citations84
US11566015B2Jan 31, 2023
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
CRINETICS PHARMACEUTICALS INC2 citations73
US11414397B2Aug 16, 2022
Somatostatin modulators and uses thereof
CRINETICS PHARMACEUTICALS INC2 citations73
US11479540B2Oct 25, 2022
Nonpeptide somatostatin type 5 receptor agonists and uses thereof
CRINETICS PHARMACEUTICALS INC5 citations72
US12479828B2Nov 25, 2025
Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
CRINETICS PHARMACEUTICALS INC0 citations62
US11608335B2Mar 21, 2023
Somatostatin modulators and uses thereof
CRINETICS PHARMACEUTICALS INC2 citations62
US11028068B2Jun 8, 2021
Somatostatin modulators and uses thereof
CRINETICS PHARMACEUTICALS INC0 citations52